Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Juraj Kultan
Observed names:
J. Kultan,
JURAJ KULTAN
Institutions:
University Hospital Olomouc,
Palacký University Olomouc
Observed institutions:
Masaryk University,
University Hospital Brno,
University Hospital Olomouc,
Deutsche Reiterliche Vereinigung,
Palacký University Olomouc
OpenAlex ID:
A5033038568
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020
·
Jonathan W Goldman
, Mikhail Dvorkin
, et al.
·
The Lancet Oncology
·
791
PDF
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
2020
·
MARTIN SVATON
, MILADA ZEMANOVA
, et al.
·
Anticancer Research
·
96
PDF
Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
2018
·
MARTIN SVATON
, MILADA ZEMANOVA
, et al.
·
Anticancer Research
·
43
PDF
Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy
2017
·
Ondrej Fiala
, Milos Pesek
, et al.
·
Tumor Biology
·
22
PDF
Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience
2020
·
Milada Zemanova
, Robert Pirker
, et al.
·
Radiology and Oncology
·
18
PDF
Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial
2021
·
Milada Zemanova
, Marketa Cernovska
, et al.
·
Cancer Treatment and Research Communications
·
17
PDF
Lung Cancer Versus “Young Cancer”: Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?
2021
·
Monika Bratova
, Kristian Brat
, et al.
·
Journal of Adolescent and Young Adult Oncology
·
10
Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
2023
·
JIRI BLAZEK
, PETR HOSEK
, et al.
·
In Vivo
·
9
PDF
Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection
2018
·
Vítězslav Kolek
, Stanislav Losse
, et al.
·
Current Medical Research and Opinion
·
9
Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry
2021
·
ONDREJ VENCLICEK
, JANA SKRICKOVA
, et al.
·
Anticancer Research
·
3
Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study
2026
·
Jiri Vachtenheim Jr
, Fernando Casas-Mendez
, et al.
·
Annals of Surgical Oncology
·
2
PDF
Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
2021
·
DANIEL KREJCI
, PETR OPALKA
, et al.
·
Anticancer Research
·
1
Autoimmune and non-autoimmune related complications of successful lung cancer treatment with pembrolizumab
2020
·
Juraj Kultan
·
Onkologie
·
1
PDF
Real-life effectiveness of first-line treatments in NSCLC patients stage IIIB/IV– data from the Czech TULUNG Registry
2020
·
Kristian Brat
, Monika Bratova
, et al.
·
European Respiratory Journal
·
1
Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic
2018
·
Miloš Pešek
, Jana Skřičková
, et al.
·
Klinicka onkologie
·
1
PDF
P1.05-054 Adjuvant Chemotherapy Uptake in Patients with NSCLC after Complete Resection: Single Institution/Single Area Experience
2017
·
Vitezslav Kolek
, Ivona Grygarkova
, et al.
·
Journal of Thoracic Oncology
·
1
Výskyt mutací genu EGFR u pacientů s NSCLC v České republice
2014
·
Ondřej Fiala
, Monika Šatánková
, et al.
·
1
Durvalumab in the treatment of limited-stage SCLC: experience from clinical practice
2026
·
Juraj Kultan
·
Onkologie
273eP Nivolumab plus chemotherapy in the neoadjuvant treatment of NSCLC: Multicenter real-world data from the Czech Republic (NINA-CZ)
2026
·
O. Bilek
, L.F. Casas Mendez
, et al.
·
ESMO Open
Long-Term Surveillance After Lung Cancer Surgery: Association Between Follow-Up Intensity and Patient Outcomes
2026
·
Martin Svaton
, Juraj Kultan
, et al.
·
SSRN Electronic Journal
Durvalumab in the treatment of limited-stage SCLC
2025
·
Juraj Kultan
·
Onkologie
Quality of life in patients with lung cancer during the modern anticancer treatment - muticenter prospective data from the Czech Republic
2025
·
Monika Bratová
, Kristian Brat
, et al.
·
European Respiratory Journal
Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study
2025
·
Martin Svaton
, Miloslav Marel
, et al.
·
Translational Cancer Research
The lung cancer patient quality of life during the first line of treatment – multicenter prospective data
2025
·
Monika Bratová
, Lenka Jakubíková
, et al.
·
Klinicka onkologie
PDF
Cemiplimab in treating locally advanced NSCLC
2023
·
Andrea Müllerová
, Juraj Kultan
·
Onkologie
PDF
Show more works
View as search
Works count:
38
Citation count:
1,026
H-index:
9
I10-index:
7
Year
Topic
Type